Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558982 · ClinicalTrials.gov registry record · Phase 2
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Georgetown University.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT05558982 is a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Georgetown University. The registered enrollment target is 22 participants, below the 183-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05558982, a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Georgetown University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG BXCL701
Study Locations (3)
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
- Medstar Washington Hospital Center - Washington D.C.
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05558982
The ClinicalTrials.gov registry entry for NCT05558982 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (88% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05558982 reports 3 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05558982 about?
NCT05558982 is a clinical study titled "BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
What is the current status of trial NCT05558982?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2023-08-16. Estimated completion is 2027-11.
What conditions does trial NCT05558982 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05558982?
The interventions under investigation include: Pembrolizumab (DRUG), BXCL701 (DRUG).
Who is sponsoring clinical trial NCT05558982?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05558982 being conducted?
This trial has 3 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.